[ Axonics Modulation Technologies raises $20M in Series C ]

Axonics Modulation Technologies has raised $20 million in Series C funding.

Founded in 2012, Axonics Modulation Technologies is a privately-held venture backed company that has developed a novel implantable neuromodulation technology for patients with urinary and bowel dysfunction and can be further directed towards several clinical indications.

Proceeds from the financing will be used to conduct a pivotal clinical study in Overactive Bladder patients to gain U.S. FDA approval and prepare Axonics to access markets around the world.

Funding  Series C
Founded  2012
Country  USA
City  Irvine, California
Founder / CEO  Raymond W. Cohen
Deal Size  $20M
Investors  Cormorant Asset Management
 Gilde Healthcare
Previous Investors  Neomed Management
 Legend Capital
 Advent Life Sciences
Edmond de Rothschild Investment Partners
 Cormorant Asset Management